Correlation Between Terns Pharmaceuticals and Protalix Biotherapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Terns Pharmaceuticals and Protalix Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Terns Pharmaceuticals and Protalix Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Terns Pharmaceuticals and Protalix Biotherapeutics, you can compare the effects of market volatilities on Terns Pharmaceuticals and Protalix Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Terns Pharmaceuticals with a short position of Protalix Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Terns Pharmaceuticals and Protalix Biotherapeutics.

Diversification Opportunities for Terns Pharmaceuticals and Protalix Biotherapeutics

-0.65
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Terns and Protalix is -0.65. Overlapping area represents the amount of risk that can be diversified away by holding Terns Pharmaceuticals and Protalix Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Protalix Biotherapeutics and Terns Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Terns Pharmaceuticals are associated (or correlated) with Protalix Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Protalix Biotherapeutics has no effect on the direction of Terns Pharmaceuticals i.e., Terns Pharmaceuticals and Protalix Biotherapeutics go up and down completely randomly.

Pair Corralation between Terns Pharmaceuticals and Protalix Biotherapeutics

Given the investment horizon of 90 days Terns Pharmaceuticals is expected to under-perform the Protalix Biotherapeutics. In addition to that, Terns Pharmaceuticals is 1.2 times more volatile than Protalix Biotherapeutics. It trades about -0.02 of its total potential returns per unit of risk. Protalix Biotherapeutics is currently generating about 0.19 per unit of volatility. If you would invest  102.00  in Protalix Biotherapeutics on September 5, 2024 and sell it today you would earn a total of  62.00  from holding Protalix Biotherapeutics or generate 60.78% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Terns Pharmaceuticals  vs.  Protalix Biotherapeutics

 Performance 
       Timeline  
Terns Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Terns Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.
Protalix Biotherapeutics 

Risk-Adjusted Performance

15 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Terns Pharmaceuticals and Protalix Biotherapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Terns Pharmaceuticals and Protalix Biotherapeutics

The main advantage of trading using opposite Terns Pharmaceuticals and Protalix Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Terns Pharmaceuticals position performs unexpectedly, Protalix Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Protalix Biotherapeutics will offset losses from the drop in Protalix Biotherapeutics' long position.
The idea behind Terns Pharmaceuticals and Protalix Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.

Other Complementary Tools

My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
CEOs Directory
Screen CEOs from public companies around the world
Fundamental Analysis
View fundamental data based on most recent published financial statements
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.